Open Access Research article

Detection of human papillomavirus DNA and p53 codon 72 polymorphism in prostate carcinomas of patients from Argentina

Gustavo J Leiros1, Silvia R Galliano1, Mario E Sember2, Tomas Kahn34, Elisabeth Schwarz3 and Kumiko Eiguchi1*

Author Affiliations

1 Catedra de Bioquimica e Inmunologia, Facultad de Medicina-Universidad del Salvador, Buenos Aires, Argentina

2 Servicio de patología, Hospital Israelita, Buenos Aires, Argentina

3 Deutsches Krebsforschungszentrum, Heidelberg, Germany

4 Expert Team Life Sciences, Deutsche Bank AG, Frankfurt, Germany

For all author emails, please log on.

BMC Urology 2005, 5:15  doi:10.1186/1471-2490-5-15

Published: 24 November 2005



Infections with high-risk human papillomaviruses (HPVs), causatively linked to cervical cancer, might also play a role in the development of prostate cancer. Furthermore, the polymorphism at codon 72 (encoding either arginine or proline) of the p53 tumor-suppressor gene is discussed as a possible determinant for cancer risk. The HPV E6 oncoprotein induces degradation of the p53 protein. The aim of this study was to analyse prostate carcinomas and hyperplasias of patients from Argentina for the presence of HPV DNA and the p53 codon 72 polymorphism genotype.


HPV DNA detection and typing were done by consensus L1 and type-specific PCR assays, respectively, and Southern blot hybridizations. Genotyping of p53 codon 72 polymorphism was performed both by allele specific primer PCRs and PCR-RFLP (Bsh1236I). Fischer's test with Woolf's approximation was used for statistical analysis.


HPV DNA was detected in 17 out of 41 (41.5 %) carcinoma samples, whereas all 30 hyperplasia samples were HPV-negative. Differences in p53 codon 72 allelic frequencies were not observed, neither between carcinomas and hyperplasias nor between HPV-positive and HPV-negative carcinomas.


These results indicate that the p53 genotype is probably not a risk factor for prostate cancer, and that HPV infections could be associated with at least a subset of prostate carcinomas.